S14G-HN (Humanin Analog)
- Category
- Longevity & Anti-Aging
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
S14G-HN is a superpotent synthetic analog of humanin, marketed for neuroprotection, cardiac and kidney protection, and general anti-aging cytoprotection. The case rests almost entirely on animal and cell studies; human evidence is low or speculative, with no established human safety profile. Its anti-apoptotic mechanism also raises an unresolved theoretical cancer concern. Not an approved drug in the US, and supply is unregulated research-grade material.
Read Full recordStudied uses & evidence
Studied uses(9)
Neuroprotection against Alzheimer's disease pathology
LowMultiple rodent studies show cognitive benefit, no human trials, and two related papers were retracted.
Cardioprotection and reduction of ischemia/reperfusion injury
LowReduced infarct size in mice and pigs, but benefit disappeared with longer ischemia; no human trials.
Anti-inflammatory effects across multiple tissues
LowReduced inflammation in small rodent and cell studies across several tissues; no human data yet.
Evidence limits
- Evidence Level
- Preclinical
All efficacy data for S14G-HN comes from cell culture and animal (primarily mouse and rat) models, with one large-animal study in pigs (Sharp et al. 2020). Human data is limited to observational and correlational studies measuring endogenous humanin levels as biomarkers in aging, Alzheimer's disease, AMD, gestational diabetes, and metabolic disease — none involving administration of exogenous S14G-HN. Endogenous humanin levels decline with age, are elevated in centenarian offspring (Barzilai/Cohen labs), are approximately 37% lower in AMD patients than age-matched controls, and correlate positively with ovarian reserve in follicular fluid. The preclinical evidence is robust and consistent across neuroprotection, cardioprotection, metabolic regulation, retinal protection, renal protection, and anti-inflammatory applications spanning multiple independent laboratories worldwide. However, the complete absence of human interventional data means no clinical efficacy or safety profile has been established.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Active cancer
ModerateMore potent humanin analog with enhanced anti-apoptotic activity. May protect tumor cells from apoptosis.
Diabetes/insulin therapy (hypoglycemia risk)
ModerateHumanin analogs improve insulin sensitivity and glucose-stimulated insulin secretion. May potentiate hypoglycemia with insulin therapy.
General cautions
Pregnancy
AbsoluteNo human safety data. Potent anti-apoptotic signaling via STAT3 pathway.
Risk summary(8)
Risks = level of concern: High · Moderate · Low · Theoretical
No established human safety profile
HighPotential cancer promotion via anti-apoptotic effects
ModerateResearch-grade product quality and purity concerns
HighModulation of IGF-1/IGFBP-3 axis
ModerateAdditive bleeding risk due to antiplatelet effects
ModerateShort and poorly characterized plasma half-life
ModerateInjection site reactions
LowUnknown effects on immune surveillance and inflammation
Theoretical
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.